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naire designed to measure the severity of the disease were analysed to assess
whether there was a difference between the treatment groups in terms of change
in severity over the 6 month period. METHODS: Latent Transition Analysis is used
to explain the responses to the questionnaire by grouping patients into categories
(severity groups) based on their responses. There are three parameters that can be
estimated using LTA; Membership probabilities (probability of belonging to a par-
ticular severity category); Transition probabilities (probability of moving to a par-
ticular severity category) and Item response probabilities. These parameters are
compared between the two treatment groups to determine if there is a difference
between them. Two covariates were included in the model to investigate their
effects. RESULTS: The analysis showed that there was no significant difference
between the treatment groups in terms of Membership probabilities or Transition
probabilities. One of the covariates was found to have a significant effect on the
responses. The effect of the covariate was different for the two treatment groups
and had an opposite effect on the Placebo group compared the effect on the Active
group. CONCLUSIONS: It has been shown that LTA can be a useful tool for analys-
ing multivariate ordinal data and that its application in clinical data analysis has
advantages over some of the more common techniques.
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OBJECTIVES: Treatment effects in survival analysis are often expressed as hazard
ratios (HR), which are not useful in cost-effectiveness analysis since they do not
entail units of health. Fortunately, parametric survival models can also be used to
estimate projected mean survival time (T). Two problems in survival analysis are
often misunderstood or ignored: non-collapsibility and omitted-variable bias due
to censoring. Non-collapsibility exists when the treatment effect changes as prog-
nostic covariates are added to the regression model, even when confounding is
absent (e.g. in a randomized controlled trial (RCT)). While HRs are known to be
non-collapsible, it has not yet been demonstrated whether non-collapsibility af-
fects T. Censoring induces bias when it is associated with patient characteristics
and no adjustment is undertaken. The objectives of this study were to disentangle
the effects of non-collapsibility and censoring bias and assess their impact on
estimates of T. METHODS: Survival, treatment and five normally distributed prog-
nostic covariates were simulated in RCT-like datasets with and without censoring.
Weibull regression models with an increasing number of covariates were used to
calculate the HR for treatment and T. RESULTS: For uncensored data, HRs de-
creased with the inclusion of additional covariates, while T remained constant. For
the censored data, T increased sharply with the inclusion of additional covariates,
while the HRs decreased. The estimates of the full model of both outcome mea-
sures were close to the means from the dataset, although the model was estimated
on censored data. CONCLUSIONS: Analysis of the synthesized data makes it pos-
sible to distinguish between the impact of non-collapsibility and censoring on HR
and T. While the HR is non-collapsible, T is collapsible. It can be used in cost-
effectiveness analysis, as long as all important prognostic factors are included in
the regression. The latter is a weakness of currently common analyses of RCT data.
RESEARCH ON METHODS - Study Design
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OBJECTIVES: To explore and quantify the extent to which the terms “efficacy” and
“effectiveness” are used consistently and correctly in and Health Technology As-
sessments (HTAs). Efficacy describes a drug’s effect in ideal and controlled circum-
stances (i.e. in clinical trials). Effectiveness describes the success of a drug in usual
or “real world” practices in which all conditions cannot be controlled. Effectiveness
is much more difficult to assess and is often measured by observational studies or
calculated by a meta-analysis of clinical trial results. METHODS: We examined 38
HTAs published from 2005-2011 covering 13 disease conditions from 6 agencies
(AHRQ, DERP, CADTH, IQWiG, NICE, and NHS Scotland), which included 115 phar-
maceutical products. We categorized each HTA based on whether their stated main
objective was to measure either clinical efficacy or clinical effectiveness. These
stated main objectives were then compared to the evidence actually evaluated in
the reported studies (ie. RCTs and/or observational studies). We quantified and
analyzed discrepancies between the stated objectives and actual objectives.
RESULTS: Of the 38 HTAs, 37 evaluated efficacy and 1 focused on effectiveness.
Eighteen reviews (47%) described their main objective, efficacy or effectiveness,
consistent with the actual evidence evaluated. Twenty reviews (53%) stated their
main objective was measuring clinical effectiveness, but presented evidence as-
sessing clinical efficacy. Of the 6 agencies, NICE and NHS Scotland showed the
highest percentages of discrepancies between stated objectives and evidence eval-
uated (80% and 100% respectively), while AHRQ and DERP had the lowest (0% and
29% respectively). CONCLUSIONS: Though the distinction between “efficacy” and
“effectiveness” is substantial, the terms are not always used appropriately or con-
sistently. Often, the uses of the terms in HTAs are misleading. This is a barrier to
clear communication, but the implications might be broader.
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OBJECTIVES: The Institute for Quality and Efficiency in Health Care (IQWiG) in
Germany evaluates benefits/harms and economic implications of medical inter-
ventions. For the purpose of cost-benefit analysis, IQWiG has developed the effi-
ciency frontier concept to determine the maximum reimbursable price for phar-
maceuticals. Within this concept benefits/harms are evaluated for each patient-
relevant endpoint. Methodological problems arise with the presence of multiple
patient-relevant endpoints because recommendations for the maximum reim-
bursable price will likely be imprecise. Conjoint analysis (CA) and analytic hierar-
chy process (AHP) are being discussed as potential approaches to aggregate multi-
ple patient-relevant endpoints. The objective of this contribution was to describe
both approaches and compare them with respect to their suitability as a method
for aggregating multiple patient-relevant endpoints within IQWiG’s efficiency
frontier concept. METHODS: A catalogue with criteria has been established to as-
sess both approaches with regard to their suitability for aggregating multiple pa-
tient-relevant endpoints. The catalogue comprises nine relevant legal and meth-
odological aspects: two criteria were identified based on legal requirements; three
criteria were included considering IQWiG method requirements; lastly, four gen-
eral methodological requirements were considered. RESULTS: Both methods were
assessed based on these criteria. Two criteria were identified that could be met by
both CA and AHP. The remaining seven criteria could be met by either CA or AHP.
None of IQWiG’s proposed approaches for prioritizing and weighting multiple pa-
tient-relevant endpoints could demonstrate to fulfill all relevant criteria when as-
sessed with regard to legal and methodological requirements. CONCLUSIONS:
With the presence of multiple patient-relevant endpoints the implementation of
the efficiency frontier concept remains unclear due to lack of methodological guid-
ance on how to aggregate multiple endpoints. There is substantial need for further
(empirical) research in methods for aggregating multiple patient-relevant end-
points.
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OBJECTIVES:During the last few years, there has been an increasing trend towards
more cost-effective monitoring of clinical trials and non-interventional studies.
Cost efficiencies can by gained with partial source data verification (SDV). The
impact of partial SDV on the accuracy of the data in these studies is unknown. In
order to propose an optimal level and method of partial SDV, we first need a better
understanding of the rates and types of discrepancies found while conducting SDV.
METHODS: PPD CRAs in NA and EMEA were invited to participate in an on-line
survey of 11 questions pertaining to level of SDV employed in studies and the
quantity/type of discrepancies found. PRELIMINARY RESULTS: Current response
rate to this survey is 28% (589/2094), with a completion rate of 83% (491/589). Only
26% (127/491) of the respondents report having used partial SDV, which was de-
fined as anything less than 100% SDV (“I always verify all of the data”). When asked
to estimate the average amount of discrepancy (all data fields) encountered be-
tween source data and CRF, two-thirds of the respondents report a typical burden
of 20% or less. Not surprisingly, the most common data discrepancies involve the
recoding of: concomitant medications (27%) followed by AEs and/or SAEs (20%). Of
those respondents who had experience with partial SDV, 32% (41/127) reported an
approach that combines ‘all data points within a subset of CRFs’ with ‘selected data
points in all CRFs’. When asked about their willingness to participate in a follow-up
interview with more detailed questions about experiences with SDV, 33% (163/491)
of the respondents answered ‘yes’. CONCLUSIONS: The results of this survey and
its planned follow-up survey will be helpful in evaluating optimal methods and
levels of partial SDV in both clinical trials and observational studies.
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OBJECTIVES: Acquisition of scientific data required for the rational decisions on
health policy has became an important tool in determining the validity of the
financing methods of treatment from public funds based on the health technology
assessment (HTA). The primary source of scientific evidence for health technology
assessment are randomized controlled trials (RCTs), because of their features (e.g.
randomization or blindness) reducing methodological bias. These features may
become a disadvantage, which markedly reduces the possibility of the transfer of
the results and conclusions to the everyday practice. In this situation an important
role begin to play pragmatic randomized controlled trials (PRCTs), providing highly
reliable information about the effectiveness in contrast to observational studies or
registries. However, an important problem is correct design and quality assess-
ment of such trials. METHODS: A systematic review in Medline through Pubmed
using the following queries: “(pragmatic OR practical OR naturalistic OR real world)
AND (design OR quality)” was performed till June 2012 to gather and systematize
the current information about pragmatic randomized trials to improve the quality
of the practical effectiveness evaluation in health technology assessment reports.
RESULTS: Using this search strategy nearly 28 000 hits were obtained. Preliminary
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